
Opinion|Videos|March 28, 2025
Academic Perspectives on the Evolving Treatment Landscape in MPNs
Author(s)Daniel Landau, MD
An expert shares their perspective on the future of care for patients with myeloproliferative neoplasms (MPNs).
Advertisement
Episodes in this series

Video content above is prompted by the following:
Please share your perspective on the future of care for patients with MPNs.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































